Jorge Cortes, MD, Augusta University, Augusta, GA, outlines some of the factors that play a role in choosing a tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML) in the frontline and relapsed/refractory (R/R) settings, including the goal of therapy, comorbidities, drug toxicities, schedule of administration, and mutations. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.